
Overview
Background
Hemamali Samaratunga MBBS (Hons) LRCP (London) MRCS (UK) FRCPA, FRCPath
- Specialist Anatomical Pathologist, Managing Director, Aquesta Specialised Uropathology
- Full Professor, University of Queensland Faculty of Medicine
- Visiting Medical Officer, Greenslopes Private Hospital
Hemamali graduated with honours from the University of Sri Lanka, Colombo Medical School and completed Pathology specialty training in Queensland. She held a number of consultant posts in both hospital and private practice. In 2008 she established Aquesta Uropathology which now provides diagnostic uropathology services to the majority of urologists in Queensland and Northern New South Wales. In addition to this she maintains a large second opinion consultation practice with requests obtained from throughout Australia and from overseas.
She is active in Genitourinary Pathology research with collaborators in Australia, USA, Canada, Karolinska Institute in Sweden and the Wellington School of Medicine in New Zealand. She held the position of Secretary of the International Society of Urological Pathology from 2015 to 2019.
She was a contributor to the 2004, 2015 and 2022 World Health Organization (WHO) books on Classification of Tumours: Pathology and Genetics of Tumours of the Urinary and Male Reproductive System. She participated in the 2015 revision of the WHO Tumour Classification in Zurich, Switzerland (4th edition) as member, Prostate Tumour Panel. She was a representative of the Expert Groups formulating structured reporting protocols for the Royal College Pathologists of Australasia on kidney, testis and prostate cancer and is currently chairperson of the structured reporting protocols for Genitourinary cancer. She is also currently the Convener for the RCPA Uropathology Quality Assurance Program.
Qualifications
MBBS (HONS) LRCP (London) MRCS (UK) FRCPA FRCPath
Current UQ Appointments
Academic Title-Professor
Non-UQ Appointments
2008 - current: Specialist Anatomical Pathologist & Managing Director, Aquesta Specialized Uropathology
2015 - Current: Visiting Medical Officer, Greenslopes Private Hospital
2003 - 2021: Visiting Medical Officer, Princess Alexandra Hospital
June 2001 - Oct 2008: Specialist Anatomical Pathologist, Sullivan Nicolaides Pathology, Brisbane
1993 - 1997: Specialist Anatomical Pathologist, Royal Brisbane Hospital
1998 - 2001: Senior Anatomical Pathologist, North Brisbane Hospitals Board
Research Interests
- Granular tumour necrosis
- Diagnosis of limited adenocarcinoma on prostate needle biopsy
- Ductal adenocarcinoma of prostate
- Mucinous adenocarcinoma of prostate
- Radical prostatectomy handling and reporting
- Micropapillary urothelial cancer
- Mimics of bladder cancer
Awards and other Esteem Indicators
2017 Admitted to Fellowship of the Royal College of Pathologists, London (FRC Path) for sustained excellence in published works
2022 Awarded the Grawitz Medal of the International Society of Urological Pathology for distinguished service to the discipline of Urological Pathology
2023 Author of the publication Percentage grade 4 tumour predicts outcome for prostate adenocarcinoma in needle biopsies from patients with advanced disease: Ten year data from the TROG 03.04 RADAR Trial. Pathology 54: 49- 54, awarded the prize of
Article of the Year by the Royal College of Pathologists of Australasia.
2024 Distinguished Fellowship Award of the Royal College Pathologists of Australasia
For distinguished service to the discipline of Urological Pathology
Keywords
Pathology, Genitourinary cancer, Prostate, Kidney, Urinary tract, Testis, Penis
Availability
- Professor Hemamali Samaratunga is:
- Available for supervision
Fields of research
Research impacts
She has over 320 scientific publications and has a Google Scholar H-index of 56 with 18150 citations. To date she has authored or co-authored 28 books, 21 book chapters and 274 peer-reviewed publications. Apart from her primary research activities Professor Samaratunga actively collaborates with other research groups and is a regular contributor - often as primary or senior author to international research consortia. One notable contribution has been her involvement in the development of artificial intelligence programs for the reporting of prostate cancer. In collaborative studies involving colleagues from the Netherlands, Sweden, Australia, New Zealand and the United States she was chosen to be one of three expert pathologists to review all cases, thus setting the gold standard for the diagnosis and grading of prostate cancer. These studies have been published in highly prestigious journals as noted in her CV. Importantly in comparative studies, the AI program informed by the findings of group of three pathologists that included Professor Samaratunga, outperformed all other AI programs.
Works
Search Professor Hemamali Samaratunga’s works on UQ eSpace
2024
Journal Article
Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer
Martini, Carmela, Logan, Jessica M., Sorvina, Alexandra, Prabhakaran, Sarita, Ung, Benjamin S Y., Johnson, Ian R. D., Hickey, Shane M., Brooks, Robert D., Caruso, Maria C., Klebe, Sonja, Karageorgos, Litsa, O’Leary, John J., Delahunt, Brett, Samaratunga, Hemamali and Brooks, Douglas A (2024). Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer. Virchows Archiv, 485 (4), 723-728. doi: 10.1007/s00428-023-03643-1
2024
Journal Article
Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics
Roberts, Matthew J., Papa, Nathan, Veerman, Hans, de Bie, Katelijne, Morton, Andrew, Franklin, Anthony, Raveenthiran, Sheliyan, Yaxley, William J., Donswijk, Maarten L., van der Poel, Henk G., Samaratunga, Hemamali, Wong, David, Brown, Nicholas, Parkinson, Robert, Gianduzzo, Troy, Kua, Boon, Coughlin, Geoffrey D., Oprea‐Lager, Daniela E., Emmett, Louise, van Leeuwen, Pim J., Yaxley, John W. and Vis, André N. (2024). Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics. BJU International, 134 (S2), 47-55. doi: 10.1111/bju.16482
2024
Journal Article
Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers
Logan, Jessica M., Martini, Carmela, Sorvina, Alexandra, Johnson, Ian R. D., Brooks, Robert D., Caruso, Maria C., Huzzell, Chelsea, Moore, Courtney R., Karageorgos, Litsa, Butler, Lisa M., Tewari, Prerna, Prabhakaran, Sarita, Hickey, Shane M., Klebe, Sonja, Samaratunga, Hemamali, Delahunt, Brett, Moretti, Kim, O’Leary, John J., Brooks, Douglas A. and Ung, Ben S.-Y. (2024). Reinterpretation of prostate cancer pathology by Appl1, Sortilin and Syndecan-1 biomarkers. Scientific Data, 11 (1) 852, 1. doi: 10.1038/s41597-024-03696-0
2024
Journal Article
Benign prostatic hyperplasia and insignificant prostate cancer with very high levels of serum prostate specific antigen
Samaratunga, Hemamali, Delahunt, Brett, Olsson, Mats, Aly, Markus, Egevad, Lars and Yaxley, John (2024). Benign prostatic hyperplasia and insignificant prostate cancer with very high levels of serum prostate specific antigen. Pathology, 56 (7), 1059-1061. doi: 10.1016/j.pathol.2024.05.013
2024
Journal Article
Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study
Egevad, Lars, Micoli, Chiara, Delahunt, Brett, Samaratunga, Hemamali, Orrason, Andri Wilberg, Garmo, Hans, Stattin, Pär and Eklund, Martin (2024). Prognosis of Gleason score 8 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. Virchows Archiv, 484 (6), 995-1003. doi: 10.1007/s00428-024-03810-y
2024
Journal Article
Prognosis of Gleason score 9–10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study
Egevad, Lars, Micoli, Chiara, Samaratunga, Hemamali, Delahunt, Brett, Garmo, Hans, Stattin, Pär and Eklund, Martin (2024). Prognosis of Gleason score 9–10 prostatic adenocarcinoma in needle biopsies: a nationwide population-based study. European Urology Oncology, 7 (2), 213-221. doi: 10.1016/j.euo.2023.11.002
2024
Journal Article
UrethroNAV: the aetiology and extent of idiopathic urethral stricture in an Australian population
Desai, Devang, Harrison, William, Raveenthiran, Sheliyan, Samaratunga, Hemamali and De Win, Gunter (2024). UrethroNAV: the aetiology and extent of idiopathic urethral stricture in an Australian population. Translational Andrology and Urology, 13 (3), 423-432. doi: 10.21037/tau-23-549
2024
Conference Publication
Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission
Vis, A., Meijer, D., Roberts, M.J., Siriwardana, A.R., Morton, A., Yaxley, J.W., Samaratunga, H., Emmett, L., Van Der Ven, P.M., Heymans, M.W., Nieuwenhuijzen, J.A., Van Der Poel, H.G., Van Donswijk, M.L., Boellaard, T.N., Schoots, I.G., Stricker, P., Haynes, A-M., Oprea-Lager, D.E., Coughlin, G.D. and Van Leeuwen, P.J. (2024). Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission. EAU24 - 39th Annual EAU Congress, Paris, France, 5-8 April 2024. Amsterdam, Netherlands: Elsevier. doi: 10.1016/s0302-2838(24)00422-6
2024
Journal Article
Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients
Samaratunga, Hemamali, Egevad, Lars, Yaxley, John, Perry-Keene, Joanna, Le Fevre, Ian, Kench, James, Matsika, Admire, Bostwick, David, Iczkowski, Kenneth and Delahunt, Brett (2024). Gleason score 3+3=6 prostatic adenocarcinoma is not benign and the current debate is unhelpful to clinicians and patients. Pathology, 56 (1), 33-38. doi: 10.1016/j.pathol.2023.10.005
2023
Journal Article
Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission tomography
Vis, André N., Meijer, Dennie, Roberts, Matthew J., Siriwardana, Amila R., Morton, Andrew, Yaxley, John W., Samaratunga, Hemamali, Emmett, Louise, van de Ven, Peter M., Heymans, Martijn W., Nieuwenhuijzen, Jakko A., van der Poel, Henk G., Donswijk, Maarten L., Boellaard, Thierry N., Schoots, Ivo G., Stricker, Phillip, Haynes, Anne-Maree, Oprea-Lager, Daniela E., Coughlin, Geoffrey D. and van Leeuwen, Pim J. (2023). Development and external validation of a novel nomogram to predict the probability of pelvic lymph-node metastases in prostate cancer patients using magnetic resonance imaging and molecular imaging with prostate-specific membrane antigen positron emission tomography. European Urology Oncology, 6 (6), 553-563. doi: 10.1016/j.euo.2023.03.010
2023
Journal Article
Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread
Sorvina, Alexandra, Martini, Carmela, Prabhakaran, Sarita, Logan, Jessica M., S-Y. Ung, Benjamin, Moore, Courtney, Johnson, Ian R.D., Lazniewska, Joanna, Tewari, Prerna, Malone, Victoria, Brooks, Robert D., Hickey, Shane M., Caruso, Maria C., Klebe, Sonja, Karageorgos, Litsa, O’Leary, John J., Delahunt, Brett, Samaratunga, Hemamali and Brooks, Doug A. (2023). Appl1, Sortilin and Syndecan-1 immunohistochemistry on intraductal carcinoma of the prostate provides evidence of retrograde spread. Pathology, 55 (6), 792-799. doi: 10.1016/j.pathol.2023.05.004
2023
Journal Article
Web-grading—a tool to test personal grading of renal and prostate cancer
Kristiansen, Glen, Schmid, Matthias, Egevad, Lars, Samaratunga, Hemamali, Varma, Murali, Inam, Kaan, Thiesen, Hans-Jürgen, Delahunt, Brett and Dai, Yulin (2023). Web-grading—a tool to test personal grading of renal and prostate cancer. APMIS, 131 (10), 528-535. doi: 10.1111/apm.13347
2023
Journal Article
Publisher Correction to: Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer
Martini, Carmela, Logan, Jessica M., Sorvina, Alexandra, Prabhakaran, Sarita, Ung, Benjamin S-Y., Johnson, Ian R. D., Hickey, Shane M., Brooks, Robert D., Caruso, Maria C., Klebe, Sonja, Karageorgos, Litsa, O’Leary, John J., Delahunt, Brett, Samaratunga, Hemamali, Brooks, Douglas A. and kConFab Consortium (2023). Publisher Correction to: Distinct patterns of biomarker expression for atypical intraductal proliferations in prostate cancer. Virchows Archiv, 1-1. doi: 10.1007/s00428-023-03666-8
2023
Journal Article
Is grading of the index (dominant) nodule in prostate cancer of greater prognostic significance than global grading?
Samaratunga, Hemamali, Egevad, Lars and Delahunt, Brett (2023). Is grading of the index (dominant) nodule in prostate cancer of greater prognostic significance than global grading?. Pathology, 56 (1), 141-142. doi: 10.1016/j.pathol.2023.08.005
2023
Journal Article
Florid basal cell hyperplasia mimics high PI-RADS score prostate cancer on mpMRI
Samaratunga, Hemamali, Hussey, David, Le Fevre, Ian K., Egevad, Lars, Sarikwal, Anubhav, Carim, Humza and Delahunt, Brett (2023). Florid basal cell hyperplasia mimics high PI-RADS score prostate cancer on mpMRI. Pathology, 56 (3), 413-415. doi: 10.1016/j.pathol.2023.07.011
2023
Journal Article
Isovalerylglycine and α-Ketobutyrate are novel biomarkers that discriminate clear cell renal cell carcinoma in biopsy specimens using two-dimensional magnetic resonance spectroscopy
Urquhart, Aaron J., Del Vecchio, Sharon J., Lukas, Darren, Ellis, Robert J., Humphries, Tyrone L.R., Ng, Keng Lim, Samaratunga, Hemamali, Galloway, Graham J., Gobe, Glenda C., Wood, Simon T. and Mountford, Carolyn E. (2023). Isovalerylglycine and α-Ketobutyrate are novel biomarkers that discriminate clear cell renal cell carcinoma in biopsy specimens using two-dimensional magnetic resonance spectroscopy. Advances in Biomarker Sciences and Technology, 5, 68-75. doi: 10.1016/j.abst.2023.08.001
2023
Journal Article
Not all tumour necrosis is granular necrosis
Samaratunga, Hemamali, Egevad, Lars and Delahunt, Brett (2023). Not all tumour necrosis is granular necrosis. Pathology, 55 (6), 903-904. doi: 10.1016/j.pathol.2023.03.019
2023
Journal Article
International Society of Urological Pathology (ISUP) consensus conference on current issues in bladder cancer. Working Group 2 : grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas
Paner, Gladell P., Kamat, Ashish, Netto, George J., Samaratunga, Hemamali, Varma, Murali, Bubendorf, Lukas, van der Kwast, Theodorus H., Cheng, Liang and the Members of the ISUP Bladder Tumor Consensus Panel (2023). International Society of Urological Pathology (ISUP) consensus conference on current issues in bladder cancer. Working Group 2 : grading of mixed grade, invasive urothelial carcinoma including histologic subtypes and divergent differentiations, and non-urothelial carcinomas. American Journal of Surgical Pathology, 48 (1), e11-e23. doi: 10.1097/pas.0000000000002077
2023
Journal Article
Prediction of prostate cancer biochemical and clinical recurrence is improved by IHC-assisted grading using Appl1, Sortilin and Syndecan-1
Logan, Jessica M., Hopkins, Ashley M., Martini, Carmela, Sorvina, Alexandra, Tewari, Prerna, Prabhakaran, Sarita, Huzzell, Chelsea, Johnson, Ian R. D., Hickey, Shane M., Ung, Ben S.-Y., Lazniewska, Joanna, Brooks, Robert D., Moore, Courtney R., Caruso, Maria C., Karageorgos, Litsa, Martin, Cara M., O’Toole, Sharon, Bogue Edgerton, Laura, Ward, Mark P., Bates, Mark, Selemidis, Stavros, Esterman, Adrian, Heffernan, Sheena, Keegan, Helen, Ní Mhaolcatha, Sarah, O’Connor, Roisin, Malone, Victoria, Carter, Marguerite, Ryan, Katie ... Brooks, Douglas A. (2023). Prediction of prostate cancer biochemical and clinical recurrence is improved by IHC-assisted grading using Appl1, Sortilin and Syndecan-1. Cancers, 15 (12) 3215, 1-12. doi: 10.3390/cancers15123215
2023
Journal Article
International opinions on grading of urothelial carcinoma: a survey among European Association of Urology and International Society of Urological Pathology members
Beijert, Irene J., Cheng, Liang, Liedberg, Fredrik, Plass, Karin, Williamson, Sean R., Gontero, Paolo, Ribal, Maria J., Babjuk, Marko, Black, Peter C., Kamat, Ashish M., Algaba, Ferran, Berman, David M., Hartmann, Arndt, Masson-Lecomte, Alexandra, Rouprêt, Morgan, Lopez-Beltran, Antonio, Samaratunga, Hemamali, Shariat, Shahrokh F., Mostafid, A. Hugh, Varma, Murali, Shen, Steven, Burger, Maximilian, Tsuzuki, Toyonori, Palou, Joan, Compérat, Eva M., Sylvester, Richard J., van der Kwast, Theo H., van Rhijn, Bas W.G. and Downes, Michelle R. (2023). International opinions on grading of urothelial carcinoma: a survey among European Association of Urology and International Society of Urological Pathology members. European Urology Open Science, 52, 154-165. doi: 10.1016/j.euros.2023.03.019
Supervision
Availability
- Professor Hemamali Samaratunga is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Completed supervision
-
2020
Doctor Philosophy
Exploring Resistance of Renal Cell Carcinoma to Sunitinib Therapy
Associate Advisor
Other advisors: Associate Professor David Vesey
-
2019
Doctor Philosophy
Cellular and molecular mechanisms of pancreatitis in atrophy and regeneration
Associate Advisor
Media
Enquiries
For media enquiries about Professor Hemamali Samaratunga's areas of expertise, story ideas and help finding experts, contact our Media team: